AbbVie has pointed to a very strong launch trajectory for Elahere, with sales rocketing to $480 million last year, almost ...

Measles cases in the European region doubled to 127,350 in 2024, reaching the highest level in nearly three decades and ...

The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as ...

According to Prof Phil Banfield, chair of the BMA council, it had become clear that the centre "no longer has a grip on the ...

One of the key open questions in cell and gene therapy is which will win out: autologous cell therapies, where the patient’s ...

Jane Chung, president and chief operating officer at Sutro, is replacing Bill Newell as chief executive as the company starts ...

It takes around seven years to develop a new drug and bring it to market. With the advent of GenAI, businesses in the life ...

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...

At Veeva Commercial Summit late 2024, web editor Nicole Raleigh spoke with Veeva Systems’ president of Europe, Chris Moore, for a discursive dive into the life sciences during the year.

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline ...

Clinical trials are constantly pushing the boundaries of innovation. Over the past few years, there’s been an explosion of advancements, such as the widespread use of biomarkers in precision ...

The European Commission has proposed new legislation to safeguard the supply of critical medicines in the EU by boosting ...